Plan A Wealth LLC Raises Position in Johnson & Johnson $JNJ

Plan A Wealth LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 495.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,036 shares of the company’s stock after acquiring an additional 13,344 shares during the period. Johnson & Johnson accounts for 1.5% of Plan A Wealth LLC’s portfolio, making the stock its 15th largest holding. Plan A Wealth LLC’s holdings in Johnson & Johnson were worth $4,246,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. Peterson Wealth Advisors LLC raised its position in Johnson & Johnson by 4.2% in the 3rd quarter. Peterson Wealth Advisors LLC now owns 1,276 shares of the company’s stock worth $338,000 after purchasing an additional 51 shares during the last quarter. New Covenant Trust Company N.A. increased its stake in shares of Johnson & Johnson by 11.3% in the 3rd quarter. New Covenant Trust Company N.A. now owns 4,505 shares of the company’s stock valued at $1,193,000 after buying an additional 456 shares during the period. Quintet Private Bank Europe S.A. raised its position in shares of Johnson & Johnson by 18.8% during the third quarter. Quintet Private Bank Europe S.A. now owns 17,519 shares of the company’s stock worth $4,638,000 after acquiring an additional 2,774 shares during the last quarter. Whalen Wealth Management Inc. lifted its stake in shares of Johnson & Johnson by 13.1% during the third quarter. Whalen Wealth Management Inc. now owns 6,503 shares of the company’s stock valued at $1,722,000 after acquiring an additional 755 shares during the period. Finally, Puff Wealth Management LLC bought a new position in Johnson & Johnson in the third quarter valued at about $206,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s oncology pipeline remains a key potential growth driver. A Phase 3 trial combining Tecvayli and Talvey reduced the relative risk of disease progression or death by 89% and the risk of death by 62% in relapsed or refractory multiple myeloma, supporting potential expansion of the company’s cancer-treatment franchise. Cancer treatment advances article
• Positive Sentiment: Several analysts remain constructive. Guggenheim reaffirmed a Buy rating with a $287 price target, while RBC Capital Markets highlighted accelerating Innovative Medicine sales as a partial offset to MedTech weakness. RBC Capital rating article
• Positive Sentiment: Longer-term commentary argues JNJ could grow faster than many investors expect through its oncology portfolio, psoriasis drug ICOTYDE, and continued momentum in Innovative Medicine. The company’s 64-year record of dividend increases also supports its defensive appeal. Johnson & Johnson growth prediction
• Neutral Sentiment: Attention is focused on JNJ’s third-quarter earnings report. Investors will look beyond revenue and earnings-per-share estimates for trends in pharmaceutical sales, MedTech performance, margins, and updated full-year guidance. Johnson & Johnson Q3 earnings preview
• Negative Sentiment: Investors remain concerned that JNJ’s valuation—around 29 times earnings—already reflects considerable confidence in future growth. MedTech competition, including pressure involving Abiomed, and a possible rebound that has yet to be demonstrated could limit near-term upside. J&J MedTech outlook
• Negative Sentiment: Dividend-focused coverage also flags biosimilar threats and ongoing talc litigation as risks that could weigh on investor sentiment despite JNJ’s dividend-growth history. Johnson & Johnson dividend risks

Johnson & Johnson Stock Down 1.1%

Shares of NYSE:JNJ traded down $2.81 during trading on Thursday, hitting $255.63. 2,608,814 shares of the company’s stock traded hands, compared to its average volume of 7,952,304. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average price of $265.71 and a 200-day moving average price of $248.78. Johnson & Johnson has a 52 week low of $184.66 and a 52 week high of $281.07. The company has a market cap of $616.05 billion, a price-to-earnings ratio of 29.61, a price-to-earnings-growth ratio of 2.50 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. During the same period in the prior year, the business earned $2.77 EPS. Johnson & Johnson’s revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, research analysts forecast that Johnson & Johnson will post 11.54 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is 62.11%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research reports. TD Cowen upped their target price on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Morgan Stanley boosted their price target on shares of Johnson & Johnson from $284.00 to $294.00 and gave the stock an “overweight” rating in a research note on Thursday, July 16th. Scotiabank restated an “outperform” rating and issued a $305.00 price objective on shares of Johnson & Johnson in a report on Thursday, July 16th. Royal Bank Of Canada raised their price objective on shares of Johnson & Johnson from $287.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Johnson Rice reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $276.22.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of Johnson & Johnson stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at $4,367,458. This trade represents a 48.37% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 87,569 shares of company stock worth $23,064,544. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.